Zobrazeno 91 - 100
of 672
pro vyhledávání: '"Emanuele Zucca"'
Publikováno v:
The Cancer Journal. 26:336-347
There are three different marginal zone lymphoma (MZLs) entities: the extranodal MZL of mucosa- associated lymphoid tissue, the splenic MZL, and the nodal MZL. The 3 MZLs share common lesions (trisomies of chromosomes 3 and 18, deletions at 6q23), an
Autor:
Alessandro Rambaldi, Alden A. Moccia, Luca Ceriani, Giovanni Martinelli, Stefanie Hayoz, Luciano Cascione, Luca Giovanella, Anastasios Stathis, Christoph Mamot, Stefan Dirnhofer, Sämi Schär, Angela Polino, Giuseppe Gritti, Andrea Bruno, Maria Cristina Pirosa, Emanuele Zucca, Teresa Ruberto
Publikováno v:
Blood Advances. 4:1082-1092
Several functional parameters from baseline (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography have been proposed as promising biomarkers of treatment efficacy in diffuse large B-cell lymphoma (DLBCL). We tested their abi
Publikováno v:
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-7 (2020)
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology
Background After several decades, cisplatin continues to be an essential drug for the treatment of several tumors, however, its potential nephrotoxicity is still a clinically relevant issue. Identification of predisposing factors for renal toxicity c
Publikováno v:
Hematological Oncology. 38:197-200
Autor:
Chiara Tarantelli, Giulio Sartori, Emanuele Zucca, Monica Binaschi, Francesca Guidetti, Filippo Spriano, Renzo Lucchini, Gaetanina Golino, Anastasios Stathis, Roberta Pittau Bordone, Eugenio Gaudio, Georg Stussi, Rachel L. Dusek, Luciano Cascione, Alessandro Bressan, Davide Rossi, Christian Rohlff, Arnima Bisht, Mario Bigioni, Robert S. Boyd, Andrea Pellacani, Nickolas Attanasio, Francesco Bertoni, Afua Adjeiwaa Mensah, Merlino Giuseppe, Elena Bernasconi, Alessio Fiascarelli, Alberto J. Arribas
Publikováno v:
Haematologica
Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematological cancers. Here, we report preclinical data on the anti-tumor activity of the first-in-class antibody drug conjugate MEN1309/OBT076 target
Autor:
A C Wotherspoon, Umberto Ricardi, M. Ponzoni, Christian Buske, Catherine Thieblemont, M. Ladetto, Peter Johnson, K. Stamatopoulos, Antonio Salar, Markus Raderer, Luca Arcaini, Emanuele Zucca
Publikováno v:
Annals of Oncology. 31:17-29
Autor:
Andrés José Maria Ferreri, Jeanette K. Doorduijn, Katerina Bakunina, Christopher P. Fox, Samar Issa, Gerald Illerhaus, Jacoline E C Bromberg, Andreas M. Schmitt, Amanda K. Herbrand, Kate Cwynarski, Lars G. Hemkens, Benjamin Kasenda, Stefan Schandelmaier, Elisabeth Schorb, Emanuele Zucca
Publikováno v:
Hematological Oncology, 37(5), 548-557. John Wiley & Sons Ltd.
The CD-20 antibody rituximab is a standard component of treatment of non-Hodgkin B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). Primary DLBCL of the central nervous system, also called primary central nervous system lymphoma (PCNS
Autor:
Attilio Guarini, Maria Gomes da Silva, Yana Stepanishyna, Gilles Salles, Igor Aurer, Martina Manni, Franck Morschhauser, Silvia Montoto, Sandra Lockmer, María Dolores Caballero Barrigón, Harald Holte, Emanuele Zucca, Martine E.D. Chamuleau, Sara Galimberti, Marielle J. Wondergem, Laura Magnano, Sara Alonso-Álvarez, Clémentine Sarkozy, Miguel Alcoceba, Luigi Marcheselli, Massimo Federico
Publikováno v:
Alonso-Álvarez, S, Manni, M, Montoto, S, Sarkozy, C, Morschhauser, F, Wondergem, M J, Guarini, A, Magnano, L, Alcoceba, M, Chamuleau, M, Galimberti, S, Gomes da Silva, M, Holte, H, Zucca, E, Lockmer, S, Aurer, I, Marcheselli, L, Stepanishyna, Y, Caballero Barrigón, M D, Salles, G & Federico, M 2021, ' Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma ', European Journal of Cancer, vol. 157, pp. 132-139 . https://doi.org/10.1016/j.ejca.2021.08.005
European Journal of Cancer, 157, 132-139. Pergamon
European Journal of Cancer, 157, 132-139. Pergamon
Background: Primary refractory (PREF) follicular lymphoma (FL) has a completely different clinical course from that of FL that responds to front-line treatments. In addition to having poor responses to salvage therapies, it seems that patients with P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a667e202072aae0de08517a7589f6531
https://research.vumc.nl/en/publications/cf01de3e-fd75-43cb-b92f-cf2546d68b2a
https://research.vumc.nl/en/publications/cf01de3e-fd75-43cb-b92f-cf2546d68b2a
Autor:
Emanuele Zucca, F. Esposito, Stephan Dirnhofer, Luciano Cascione, Luca Ceriani, Luca Giovanella, Sämi Schär, Christoph Mamot, Giuseppe Gritti, Federico Dalmasso, Maria Cristina Pirosa, Stephane Chauvie, Andrea Bruno, Alessandro Rambaldi, Stefanie Hayoz, Lisa Milan
Publikováno v:
Hematological oncologyREFERENCES. 40(1)
Functional parameters from positron emission tomography (PET) seem promising biomarkers in various lymphoma subtypes. This study investigated the prognostic value of PET radiomics in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP
Autor:
Emanuele Zucca, Stefanie Hayoz, Andrea Bruno, F. Esposito, Luca Ceriani, Alessandro Rambaldi, Stephan Dirnhofer, S. Chauvie, Sämi Schär, Luciano Cascione, Lisa Milan, Federico Dalmasso, Maria Cristina Pirosa, Christoph Mamot, Luca Giovanella, Giuseppe Gritti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b4a20ec373d3c9ae9765dcbe81c7a6e
https://doi.org/10.1002/hon.2935/v2/response1
https://doi.org/10.1002/hon.2935/v2/response1